// App-Quantinova.ai

240 : Eribulin has anti-tumor activity in a preclinical model of merkel cell carcinoma

Researchers

Presenter

  • K. Miyamoto

Principal Investigators

  • T. Yanagi

  • T. Maeda

  • S. Kitamura

  • H. Ujiie

Medical Centers

  • Dermatology, Hokkaido Daigaku, Sapporo, Hokkaido, Japan

Locations

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Merkel cell carcinoma

  • Skin carcinoma

  • Solid malignancies

Biomarkers

  • p53

  • Retinoblastoma protein

Drug/Treatment

  • Docetaxel

  • Etoposide

  • Etoposide phosphate

  • Cisplatin

  • Eribulin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved